Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Apr;50(4):1578-80.
doi: 10.1128/AAC.50.4.1578-1580.2006.

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV

Mary B Wire  1 , Katherine L Baker, Lori S Jones, Mark J Shelton, Yu Lou, Greg J Thomas, M Michelle Berrey
Affiliations
Randomized Controlled Trial

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV

Mary B Wire et al. Antimicrob Agents Chemother. 2006 Apr.

Abstract

To compare the effect of ritonavir on plasma amprenavir pharmacokinetics, healthy adults received either fosamprenavir (700 mg twice a day [BID]) or amprenavir (600 mg BID) alone and in combination with ritonavir (100 mg BID). Ritonavir increased plasma amprenavir pharmacokinetic parameters to a similar extent when coadministered with either fosamprenavir or amprenavir.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Median plasma APV concentration-time profiles.
See this image and copyright information in PMC

References

    1. Furfine, E. S., C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein. 2004. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48:791-798. - PMC - PubMed
    1. Gathe, J. C., P. Ive, R. Wood, D. Schurmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice daily nelfinavir in naïve HIV-1 infected patients. AIDS 18:1529-1537. - PubMed
    1. Rodriguez-French, A., J. Boghossian, G. E. Gray, J. P. Nadler, A. R. Quinones, G. E. Sepulveda, J. M. Millard, and P. G. Wannamaker. 2004. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1 infected patients. J. Acquir. Immune Defic. Syndr. 35:22-32. - PubMed
    1. Wire, M. B., C. Ballow, S. L. Preston, C. W. Hendrix, P. J. Piliero, Y. Lou, and D. S. Stein. 2004. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 18:897-907. - PubMed
    1. Wood, R., K. Arasteh, H.-J. Stellbrink, E. Teofilo, F. Raffi, R. B. Pollard, J. Eron, J. Yeo, J. Millard, M. B. Wire, and O. J. Naderer. 2004. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 48:116-123. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources